Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc. has demonstrated significant growth in its NeXT Personal Dx volumes, with a reported increase of 41% quarter-over-quarter in Q4'25, suggesting strong demand for its genomic services and positive momentum alongside a key commercial partnership with Tempus. The recent acquisition of Medicare coverage and pricing for the NeXT Personal MRD test marks a critical advancement, as it positions the product competitively in the oncology market, particularly in breast cancer detection and recurrence monitoring. Furthermore, the company has established a superior performance benchmark with its NeXT Personal test, achieving a notable 40% positivity rate in the critical ctDNA range, underlining its potential to enhance early cancer detection and solidifying its value proposition in personalized medicine.

Personalis, Inc. has issued lower guidance for Q4 2025, attributing this downturn to a general slowdown in biopharmaceutical activity and logistical challenges in handling global samples. The company also revised its 2025 revenue forecast down to a range of $68 million to $73 million, representing a year-over-year decline of 5% to 12%, which underscores a weakening demand for its pharma services. Additionally, despite raising $109 million through its ATM facility, the persistent financial losses and existing debt raise concerns about the company’s ability to achieve or maintain profitability moving forward.